Clinical trials: Frontotemporal Lobar Degeneration (FTLD)
Frontotemporal Dementia, Behavioral Variant, Alzheimer Disease
ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions
ECOCAPTURE@HOME is a study which is currently being developed with the objective to capture the behavioral signature of apathy in everyday life context through remote monitoring of participants' behavior for about one month.
- Trial name
- @HOME (NCT04865172)
- Testing
- Remote collection of passive and active data for 28 consecutive days
- Where
- France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alzheimer's Disease, Healthy Adult Participants
Ultra-high-performance Positron Emission Tomography (PET) of Synaptic Density, Reactive Astrogliosis and Tau in Alzheimer's Disease
AIM: to investigate the relationship between synaptic density, tau and reactive astrogliosis in Alzheimer's disease (AD) versus healthy controls and centenarians.
- Trial name
- NCT07906054
- Testing
- 18F-SMBT-1 PET, 18F-SynVesT-1 PET, 18F-MK-6240 PET
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.
Alzheimer Disease, Cognitive Impairment
The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers
The goal of this observational study is to determine whether the early adoption of blood-based biomarkers for Alzheimer's disease is associated with an impact on etiological diagnosis, patient's management, emotional impact…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Dementia, Neurodegenerative Diseases
- Trial name
- PLASMAR (NCT06246019)
- Testing
- Early adoption of blood-based biomarkers for Alzheimer's disease
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hospital del Mar Research Institute (IMIM)
Progressive Supranuclear Palsy (PSP)
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
- Trial name
- NCT04539041
- Testing
- antisense oligonucleotide
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Alzheimer Disease
Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment
The objective of the study is to investigate the clinical validity of tau-PET with [18F]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia
- Trial name
- IDV of tau-PET (NCT06618872)
- Testing
- PET/CT with RO958 (experimental)
- Where
- 2 sites in Switzerland
- Volunteers
- 120 people
- Sponsor
- University Hospital, Geneva
Alzheimer Disease, Lewy Body Dementia (LBD)
The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias
The study aims to use advanced brainwave recordings of electroencephalogram (EEG) to understand early signs of Alzheimer's disease (AD) in people with mild memory problems, known as amnestic Mild Cognitive Impairment (MCI).
- Conditions
- Alzheimer Disease, Lewy Body Dementia (LBD), Mild Alzheimer Disease, Frontotemporal Dementia (FTD)
- Trial name
- NCT06826157
- Testing
- Electroencephalogram, 3 Tesla MRI, Apolipoprotein E genetic test
- Where
- Italy
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Alzheimer Disease
COGNIShunt® System for Alzheimer's Disease
This is a study of the effect on the progression of Alzheimer's Disease of a surgically implanted shunt (tube) to increase the flow of cerebrospinal fluid and improve the clearance of potential neurotoxins from the fluid bathing…
- Trial name
- NCT00056628
- Testing
- The COGNIShunt® System
- Volunteers
- 250 people
- Sponsor
- Eunoe
PPA, Non-fluent Aphasia
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with…
- Conditions
- PPA, Non-fluent Aphasia, Apraxia of Speech, Primary Progressive Non-fluent Aphasia
- Trial name
- NCT01818661
- Testing
- AV-1451
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
The objectives of the study are to; (1) estimate the change in disease -related cognitive decline over 1 year on a battery of cognitive tests administered to participants with early-stage symptomatic Behavioral Variant…
- Trial name
- FORWARD (NCT03088956)
- Testing
- Assessments
- Where
- 12 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Biogen
Frontotemporal Dementia, Frontotemporal Degeneration
Voices Of Individuals: Challenges and Experiences Of bvFTD
The VOICE Of bvFTD study is a telephone interview research study about life with or at risk for behavioral variant frontotemporal dementia (bvFTD).
- Conditions
- Frontotemporal Dementia, Frontotemporal Degeneration, Frontotemporal Dementia, Behavioral Variant, FTD
- Trial name
- NCT04060082
- Testing
- Telephone Interview
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Pennsylvania
Cognition Disorders
18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study
Approximately 50 participants enrolled in the LEARN study (NCT02488720) will be enrolled in the LEARN-Tau study. The study designed to evaluate the imaging characteristics of 18F-AV-1451 in participants enrolled in the LEARN…
- Trial name
- LEARN-Tau (NCT02850146)
- Testing
- 18F-AV-1451
- Where
- 7 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Mild Cognitive Impairment
Longitudinal Cognitive Assessment by BoCA
The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia
- Trial name
- BoCA (NCT04114994)
- Testing
- Boston Cognitive Assessment (BoCA)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Light LLC
Dementia, Dementia, Vascular
The Care Ecosystem Consortium Effectiveness Study
The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures.
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Alzheimers
- Trial name
- NCT05669365
- Testing
- Care Ecosystem
- Where
- 6 sites in United States
- Volunteers
- 1,227 people
- Sponsor
- University of California, San Francisco
Dementia, Alzheimer Disease
Care Ecosystem: Navigating Patients and Families Through Stages of Care
This is a randomized clinical trial evaluating the benefits of a program that supports model care for persons with dementia and their family caregivers. Subjects were recruited from California, Nebraska and Iowa.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Lewy Body Disease
- Trial name
- NCT02213458
- Testing
- Navigated Care
- Where
- 2 sites in United States
- Volunteers
- 1,560 people
- Sponsor
- University of California, San Francisco
Dementia Frontotemporal
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101…
- Trial name
- NCT07154485
- Testing
- NS101 IV infusion
- Volunteers
- 15 people
- Sponsor
- Hee-Jin Kim
Cognition, Affect (Mental Function)
ETASCAI Pilot Project
This pilot study aims to investigate the chronic effects of ETAS® on cognitive, affective and inflammatory outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.
- Conditions
- Cognition, Affect (Mental Function), Inflammation
- Trial name
- NCT06790849
- Testing
- Active 1 ETAS®, Active 2 ETAS®
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Reading
Alzheimer Disease, Alzheimer Dementia
Multimodal Ocular Imaging in Neurodegeneration
Alzheimer's disease (AD) and frontotemporal dementia (FTD) are two of the most common types of age-related neurodegenerative disorders.
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
- Trial name
- NCT03699644
- Testing
- Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Frontotemporal Dementia, Caregiver Burden
STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners
The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons…
- Conditions
- Frontotemporal Dementia, Caregiver Burden, Primary Progressive Aphasia (PPA), Corticobasal Syndrome
- Trial name
- STELLA-FTD (NCT06613204)
- Testing
- STELLA-FTD Control, STELLA-FTD Test
- Where
- United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Insomnia, Dementia
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team.
- Conditions
- Insomnia, Dementia, Frontotemporal Dementia
- Trial name
- NCT06093126
- Testing
- Lemborexant 5 MG
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Nova Scotia Health Authority